LAWSUITS NEWS & LEGAL INFORMATION
FDA Reviews Saxagliptin (Onglyza and Kombiglyze XR) For Heart Failure Risk
Were you looking for Saxagliptin - Onglyza and Kombiglyze XR Side Effects lawsuits?
Washington, DC: The Food and Drug Administration (FDA) has requested clinical trial data from the manufacturer of saxagliptin to investigate a possible association between use of the type 2 diabetes drug and heart failure.
The request resulted from a study published in the New England Journal of Medicine (NEJM), which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough, with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment.
The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin. The manufacturer is expected to submit the trial data to the FDA by early March 2014, after which the FDA will conduct a thorough analysis and report findings publicly.
At this time, the FDA considers information from the NEJM study to be preliminary. Analysis of the saxagliptin clinical trial data is part of a broader evaluation of, all type 2 diabetes drug therapies and cardiovascular risk.
Saxagliptin is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It works by increasing the amount of insulin produced by the body after meals, when blood sugar is high.
Last updated on
The request resulted from a study published in the New England Journal of Medicine (NEJM), which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough, with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment.
The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin. The manufacturer is expected to submit the trial data to the FDA by early March 2014, after which the FDA will conduct a thorough analysis and report findings publicly.
At this time, the FDA considers information from the NEJM study to be preliminary. Analysis of the saxagliptin clinical trial data is part of a broader evaluation of, all type 2 diabetes drug therapies and cardiovascular risk.
Saxagliptin is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It works by increasing the amount of insulin produced by the body after meals, when blood sugar is high.
Legal Help
If you or a loved one has suffered similar damages or injuries, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.Last updated on
DIABETES MEDICATION SIDE EFFECTS LEGAL ARTICLES AND INTERVIEWS
Sen. Warren Raises the Alarm over Catalent/Novo Nordisk Merger
Ozempic and Addiction: A Potential Game-Changer?
Ozempic Linked to Serious Pain in the Pocketbook
November 1, 2024
On October 10, U.S. Senator Elizabeth Warren sent a letter to Federal Trade Commission (FTC) Chair Lina Khan, urging the FTC to closely review a proposed merger between Novo Nordisk and Catalent. Catalent is one of the very few suppliers that provide specialized development and manufacturing services to GLP-1 manufacturers. The letter urges the FTC to block the deal if it could hurt Americans by limiting competition and raising the price of life-saving medicine. Not coincidentally, killing competition might also limit the development of drugs without the dangerous side effects of Ozempic. READ MORE
Ozempic and Addiction: A Potential Game-Changer?
October 23, 2024
Ozempic, a semaglutide, is a medication primarily used to treat type 2 diabetes. It works by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels. However, recent studies have revealed a surprising potential benefit: addiction reduction, specifically with reference to alcohol and opioid abuse. READ MORE
Ozempic Linked to Serious Pain in the Pocketbook
September 19, 2024
On September 24, the Senate Committee on Health Education Labor and Pensions (HELP) will hear testimony from Lars Jorgensen, Novo Nordisk CEO, about why American consumers pay as much as ten times more for Ozempic and Wegovy than patients in the U.K. and the Netherlands. The popular diabetes and weight loss drugs have already been linked to serious side effects. These well-documented Ozempic side effects include stomach paralysis, a rare form of blindness, thyroid cancer and bowel obstruction. READ MORE
READ MORE Drugs/Medical Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News